Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2014

01-03-2014 | Hepatobiliary Tumors

Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?

Authors: Liang-He Yu, Nan Li, Jie Shi, Wei-Xing Guo, Meng-Chao Wu, Shu-Qun Cheng

Published in: Annals of Surgical Oncology | Issue 3/2014

Login to get access

Abstract

The Hepatitis B virus (HBV) is an important etiological factor for hepatocarcinogenesis, because HBV DNA load and HBV reactivation are major risks that influence the long-term survival of hepatocellular carcinoma (HCC) patients who underwent hepatectomy and, thus, may cause postoperative liver function deterioration, tumor recurrence, and reduce patient’s overall survival. However, anti-HBV therapy can suppress HBV replication, improve the remnant liver function, render patients better able to tolerate HCC treatments, and may even improve their prognosis. In this paper, an anti-HBV therapy that benefits the prognosis of HBV-related HCC following hepatectomy is reviewed.
Literature
1.
El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132(7):2557–76.PubMedCrossRef
2.
Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006;131(6):1743–51.PubMedCrossRef
3.
Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65-73.PubMedCrossRef
4.
Sun HC, Tang ZY, Ma ZC, et al. The prognostic factor for outcome following second resection for intrahepatic recurrence of hepatocellular carcinoma with a hepatitis B virus infection background. J Cancer Res Clin Oncol. 2005;131(5):284–8.PubMedCrossRef
5.
Sangiovanni A, Del Ninno E, Fasani P, et al. Increased survival of cirrhotic patients with a hepatocellular carcinoma detected during surveillance. Gastroenterology. 2004;126(4):1005–14.PubMedCrossRef
6.
7.
Yanaga K. Current status of hepatic resection for hepatocellular carcinoma. J Gastroenterol. 2004;39(10):919–26.PubMedCrossRef
8.
Lo CM, Liu CL, Chan SC, et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg. 2007;245(6):831–42.PubMedCrossRef
9.
Dienstag JL, Goldin RD, Heathcote EJ, et al. Histological outcome during long-term lamivudine therapy. Gastroenterology. 2003;124(1):105–17.PubMedCrossRef
10.
Akuta N, Suzuki F, Suzuki Y, et al. Favorable efficacy of long-term lamivudine therapy in patients with chronic hepatitis B: an 8-year follow-up study. J Med Virol. 2005;75(4):491–8.PubMedCrossRef
11.
Liaw YF, Sung JJ, Chow WC, et al. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med. 2004;351(15):1521–31.PubMedCrossRef
12.
Li N, Lai EC, Shi J, et al. A comparative study of antiviral therapy after resection of hepatocellular carcinoma in the immune-active phase of hepatitis B virus infection. Ann Surg Oncol. 2010;17(1):179–85.PubMedCrossRef
13.
Kuzuya T, Katano Y, Kumada T, et al. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol. 2007;22(11):1929–35.PubMedCrossRef
14.
Yang HI, Lu SN, Liaw YF, et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med. 2002;347(3):168–74.PubMedCrossRef
15.
Yu MW, Yeh SH, Chen PJ, et al. Hepatitis B virus genotype and DNA level and hepatocellular carcinoma: a prospective study in men. J Natl Cancer Inst. 2005;97(4):265–72.PubMedCrossRef
16.
Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology. 2006;130(3):678–86.PubMedCrossRef
17.
Kubo S, Hirohashi K, Tanaka H, et al. Virologic and biochemical changes and prognosis after liver resection for hepatitis B virus-related hepatocellular carcinoma. Dig Surg. 2001;18(1):26–33.PubMedCrossRef
18.
Kim BK, Park JY, Kim do Y, et al. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int. 2008;28(3):393–401.PubMedCrossRef
19.
Yang T, Lu JH, Zhai J, et al. High viral load is associated with poor overall and recurrence-free survival of hepatitis B virus-related hepatocellular carcinoma after curative resection: a prospective cohort study. Eur J Surg Oncol. 2012;38(8):683–91.
20.
Urata Y, Kubo S, Takemura S, et al. Effects of antiviral therapy on long-term outcome after liver resection for hepatitis B virus-related hepatocellular carcinoma. J Hepatobiliary Pancreat Sci. 2012;19(6):685–96.
21.
Chen YC, Chu CM, Yeh CT, Liaw YF. Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study. Hepatol Int. 2007;1(1):267–73.PubMedCrossRef
22.
Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97(11):2886–95.PubMedCrossRef
23.
Yeo W, Chan PK, Zhong S, et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol. 2000;62(3):299–307.PubMedCrossRef
24.
Leaw SJ, Yen CJ, Huang WT, Chen TY, Su WC, Tsao CJ. Preemptive use of interferon or lamivudine for hepatitis B reactivation in patients with aggressive lymphoma receiving chemotherapy. Ann Hematol. 2004;83(5):270-5.PubMedCrossRef
25.
Kubo S, Nishiguchi S, Hamba H, et al. Reactivation of viral replication after liver resection in patients infected with hepatitis B virus. Ann Surg. 2001;233(1):139–45.PubMedCrossRef
26.
Huang L, Li J, Lau WY, et al. Perioperative reactivation of hepatitis B virus replication in patients undergoing partial hepatectomy for hepatocellular carcinoma. J Gastroenterol Hepatol. 2012;27(1):158–64.PubMedCrossRef
27.
Huang GL, Eric C. H. Lau, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013;257(3):490–505.PubMedCrossRef
28.
Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Miyazaki M. Immunosuppression following surgical and traumatic injury. Surg Today. 2010;40(9):793–808.PubMedCrossRef
29.
Liu CJ, Chen PJ, Chen DS, Kao JH. Hepatitis B virus reactivation in patients receiving cancer chemotherapy: natural history, pathogenesis, and management. Hepatol Int. 2013;7(2):316–26.
30.
Tateishi R, Shiina S, Teratani T, et al. Percutaneous radiofrequency ablation for hepatocellular carcinoma. An analysis of 1000 cases. Cancer. 2005;103(6):1201–1209.PubMedCrossRef
31.
Wu FS, Zhao WH, Liang TB, et al. Survival factors after resection of small hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int. 2005;4(3):379–84.PubMed
32.
33.
Thia TJ, Lui HF, Ooi LL, et al. A study into the risk of exacerbation of chronic hepatitis B after liver resection for hepatocellular carcinoma. J Gastrointest Surg. 2007;11(5):612–8.PubMedCrossRef
34.
Koda M, Nagahara T, Matono T, et al. Nucleotide analogs for patients with HBV-related hepatocellular carcinoma increase the survival rate through improved liver function. Intern Med. 2009;48(1):11–7.PubMedCrossRef
35.
Yin JH, Li N, Han YF, et al. Effect of antiviral treatment with nucleot(s)ide analogues on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: a two-stage longitudinal clinical study. J Clin Oncol. 2013;31(29):3647–55.
36.
Chan AC, Chok KS, Yuen WK, et al. Impact of antiviral therapy on the survival of patients after major hepatectomy for hepatitis B virus-related hepatocellular carcinoma. Arch Surg. 2011;146(6):675–81.PubMedCrossRef
37.
Chuma M, Hige S, Kamiyama T, et al. The influence of hepatitis B DNA level and antiviral therapy on recurrence after initial curative treatment in patients with hepatocellular carcinoma. J Gastroenterol. 2009;44(9):991–9.PubMedCrossRef
38.
Kubo S, Tanaka H, Takemura S, et al. Effects of lamivudine on outcome after liver resection for hepatocellular carcinoma in patients with active replication of hepatitis B virus. Hepatol Res. 2007;37(2):94–100.PubMedCrossRef
39.
Hosaka T, Suzuki F, Kobayashi M, et al. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy. Liver Int. 2010;30(10):1461–70.PubMedCrossRef
40.
Kardinal CG, Moertel CG, Wieand HS, et al. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer. 1993;71(7):2187–90.PubMedCrossRef
41.
Wu CY, Chen YJ, Ho HJ, et al. Association between nucleoside analogues and risk of hepatitis B virus-related hepatocellular carcinoma recurrence following liver resection. JAMA. 2012;308(18):1906–14.PubMedCrossRef
42.
Miao RY, Zhao HT, Yang HY, et al. Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: a meta-analysis. World J Gastroenterol. 2010;16(23):2931–42.PubMedCrossRef
43.
Jin YJ, Shim JH, Lee HC, et al. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma. J Gastroenterol Hepatol. 2011;26(9):1380–8.PubMed
44.
EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009;50(2):227–42.
45.
46.
Liaw YF, Leung N, Kao JH, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int. 2008;2(3):263–83.PubMedCrossRef
47.
Keeffe EB, Dieterich DT, Han SH, et al. A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol. 2008;6(12):1315–41; quiz 1286.PubMedCrossRef
48.
Lim SG, Mohammed R, Yuen MF, Kao JH. Prevention of hepatocellular carcinoma in hepatitis B virus infection. J Gastroenterol Hepatol. 2009;24(8):1352–7.PubMedCrossRef
49.
Yuen MF, Tanaka Y, Fong DY, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009;50(1):80–8.PubMedCrossRef
50.
Lai CL, Yuen MF. The natural history and treatment of chronic hepatitis B: a critical evaluation of standard treatment criteria and end points. Ann Intern Med. 2007;147(1):58–61.PubMedCrossRef
51.
Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol. 2007;21(Suppl C):5C–24C.PubMedCentralPubMed
52.
Fung J, Yuen MF, Yuen JC, Wong DK, Lai CL. Low serum HBV DNA levels and development of hepatocellular carcinoma in patients with chronic hepatitis B: a case-control study. Aliment Pharmacol Ther. 2007;26(3):377–82.PubMedCrossRef
53.
Kojima M, Udo K, Takahashi Y, et al. Correlation between titer of antibody to hepatitis B core antigen and presence of viral antigens in the liver. Gastroenterology. 1977;73(4 Pt 1):664–7.PubMed
54.
Omata M, Afroudakis A, Liew CT, Ashcavai M, Peters RL. Comparison of serum hepatitis B surface antigen (HBsAg) and serum anticore with tissue HBsAg and hepatitis B core antigen (HBcAg). Gastroenterology. 1978;75(6):1003–9.PubMed
55.
Hu KQ. Occult hepatitis B virus infection and its clinical implications. J Viral Hepat. 2002;9(4):243–57.PubMedCrossRef
Metadata
Title
Does Anti-HBV Therapy Benefit the Prognosis of HBV-Related Hepatocellular Carcinoma Following Hepatectomy?
Authors
Liang-He Yu
Nan Li
Jie Shi
Wei-Xing Guo
Meng-Chao Wu
Shu-Qun Cheng
Publication date
01-03-2014
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 3/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-013-3320-z

Other articles of this Issue 3/2014

Annals of Surgical Oncology 3/2014 Go to the issue

Melanomas

Prognosis of Patients with Melanoma and Microsatellitosis Undergoing Sentinel Lymph Node Biopsy

Healthcare Policy and Outcomes

Follow-Up After Curative Cancer Surgery: Understanding Costs and Benefits

Hepatobiliary Tumors

Morbidity and Mortality in 1,174 Patients Undergoing Hepatic Parenchymal Transection Using a Stapler Device

Gastrointestinal Oncology

Morbidity Associated with Colostomy Reversal After Cytoreductive Surgery and HIPEC

Hepatobiliary Tumors

The Significance of Classifying Microvascular Invasion in Patients with Hepatocellular Carcinoma

Breast Oncology

Reducing Persistent Postoperative Pain and Disability 1 Year After Breast Cancer Surgery: A Randomized, Controlled Trial Comparing Thoracic Paravertebral Block to Local Anesthetic Infiltration